Intracoronary Stent Deployment without Antiplatelet Agents in a Patient with Idiopathic Thrombocytopenic Purpura.
- Author:
Hun Jun PARK
1
;
Ki Bae SEUNG
;
Pum Joon KIM
;
Hyun Hee KANG
;
Chan Seok PARK
;
Uk Hyun KIL
;
Min Seok CHOI
;
Sang Hong BAEK
;
Jae Hyung KIM
;
Kyu Bo CHOI
Author Information
- Publication Type:Case Report
- Keywords: Myocardial infarction; Microvascular integrity
- MeSH: Arteries; Chest Pain; Constriction, Pathologic; Coronary Angiography; Female; Hemorrhage; Humans; Immunoglobulins; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors*; Platelet Count; Purpura, Thrombocytopenic, Idiopathic*; Stents*; Thrombocytopenia; Thrombosis
- From:Korean Circulation Journal 2007;37(2):87-90
- CountryRepublic of Korea
- Language:English
- Abstract: Deciding on the appropriate antiplatelet therapy is a challenge when treating patients with idiopathic thrombocytopenic purpura (ITP) and who are undergoing percutaneous coronary intervention (PCI). We describe here a case of PCI in a patient with chronic, refractory ITP. A 61-year-old woman presented with exertional chest pain and a low platelet count (4 x 109/L) at admission. Coronary angiography revealed 99% stenosis of the mid left anterior descending artery and 95% stenosis of the mid left circumflex artery. Antiplatelet agents couldn't be administered because of the risk of bleeding. After transfusion of platelets and administering intravenous immunoglobulin, we deployed baremetal stents in both lesions without administering any antiplatelet agents. Although focal in-stent restenosis developed 5 months later, there was no episode of stent thrombosis despite not using antiplatelet agents. The present case suggests that the rate of stent thrombosis may be lower was previously thought and antiplatelet therapy may be considered on a case by case for patient suffering with thrombocytopenia.
